Basics and recent advances in peptide and protein drug delivery

By B. Bruno, Geoffrey D. Miller, Carol S. Lim. Therapeutic delivery, 2013

683 citations recorded by the source corpus.

While the peptide and protein therapeutic market has developed significantly in the past decades, delivery has limited their use. Although oral delivery is preferred, most are currently delivered intravenously or subcutaneously due to degradation and limited absorption in the gastrointestinal tract. Therefore, absorption enhancers, enzyme inhibitors, carrier systems and stability enhancers are being studied to facilitate oral peptide delivery. Additionally, transdermal peptide delivery avoids the issues of the gastrointestinal tract, but also faces absorption limitations. Due to proteases, opsonization and agglutination, free peptides are not systemically stable without modifications. This review discusses oral and transdermal peptide drug delivery, focusing on barriers and solutions to absorption and stability issues. Methods to increase systemic stability and site-specific delivery are also discussed.

Subfields: Molecular Biology, Pharmaceutical Science

View Paper: https://www.semanticscholar.org/paper/faf671bbfc04c4069e14a915056844a90368c4da

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

Bioactive protein hydrolysates in the functional food ingredient industry: Overcoming current challenges (2017, background): “enzyme inhibitors, such as trypsin inhibitors, and by the administration of absorption enhancers.((73))”
Artificial intelligence to deep learning: machine intelligence approach for drug discovery (2021, background): “Peptides are a biologically active small chain of around 2–50 amino acids, which are increasingly being explored for therapeutic purposes as they have the ability to cross the cellular barrier and can reach the desired target site [109].”
Smart nanoparticles for cancer therapy (2023, background): “296 299 For example, carnosine drugs that can be used for cancer treatment exist in human blood for less than 2 min, but after self-assembly to form nano drugs, the half-life and anti-cancer ability in vivo are signi ﬁ cantly enhanced.”